Novasep has performed a proof-of-concept study of McSAF’s bioconjugation technology, producing the first batch of Adcitmer ADC at its facility in Le Mans. The CDMO said it leveraged its specific expertise and purpose-built capabilities to support McSAF’s preclinical studies underway in Merkel cell carcinoma, a rare and aggressive skin cancer and a type of neuroendocrine cancer.

“The process transfer of our proprietary bioconjugation technology, McSAF Inside, to Novasep is a huge step in McSAF's story and is a validation of the manufacturing process for our future product developments,” said Marie-Claude Viaud-Massuard, McSAF’s chief scientific officer. “Now, with this pilot batch, we will be able to illustrate further the therapeutic relevance of our ADC for metastatic Merkel cell carcinoma patients currently with unmet medical needs.”

Based in Tours, McSAF specializes in bioconjugation tools to design ADCs for oncology and beyond. Adcitmer is its first lead product candidate.

Author: Elaine Burridge, Freelance Journalist